The stock rose after a promising full-year 2018 earnings report and then rapidly began sliding back to multiyear lows. What's going on?
News & Analysis: Rigel Pharmaceuticals
RIGL earnings call for the period ending March 31, 2019.
The pharma company announced full-year 2018 operating results.
RIGL earnings call for the period ending December 31, 2018.
This small-cap stock had a rough 2018, but the company just launched its first drug product. Will it be enough to regain Wall Street's trust?
The biotech launched Tavalisse during the second quarter. Here's what you need to know.
Wall Street's pinned high hopes on these four biotech stocks.
The pharmaceutical company announced second-quarter 2018 earnings results.
Learn how these stocks defied a down market.
The company's lead drug candidate was approved by regulators -- for real this time.